Overview

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

Status:
Recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
Pfizer
Treatments:
Poly(ADP-ribose) Polymerase Inhibitors
Talazoparib